Phibro Animal Health Corporation (NASDAQ:PAHC) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts give Phibro Animal Health an average rating of "Hold" from seven firms (1 sell, 3 hold, 2 buy, 1 strong buy) with a mean 12‑month target price of $42.40.
• The company beat the quarter with $0.76 EPS vs. $0.72 expected and $383.5M revenue vs. $367.0M expected, while FY2026 EPS guidance of $2.98–$3.10 is roughly in line with the Street (~3.03).
• Phibro declared a quarterly dividend of $0.12 (payable June 24, record June 3) and disclosed insider selling (CEO sold 7,040 shares; insiders sold 170,758 shares in the last 90 days) despite insiders owning a large stake.

Shares of Phibro Animal Health Corporation (NASDAQ:PAHC - Get Free Report) have received an average rating of "Hold" from the seven ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating, two have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $42.40.

Several research analysts recently commented on PAHC shares. Morgan Stanley set a $49.00 target price on shares of Phibro Animal Health in a report on Friday, February 6th. Zacks Research raised shares of Phibro Animal Health from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, March 11th. Finally, Citigroup began coverage on shares of Phibro Animal Health in a research note on Wednesday, April 15th. They issued a "neutral" rating and a $62.00 price target for the company.

Phibro Animal Health Price Performance

Shares of PAHC stock opened at $58.50 on Thursday. The company has a quick ratio of 1.22, a current ratio of 3.05 and a debt-to-equity ratio of 2.14. Phibro Animal Health has a 12-month low of $19.00 and a 12-month high of $60.08. The firm has a fifty day moving average of $54.07 and a 200-day moving average of $46.48. The firm has a market capitalization of $2.37 billion, a price-to-earnings ratio of 26.00, a price-to-earnings-growth ratio of 0.86 and a beta of 0.61.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its earnings results on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a return on equity of 38.28% and a net margin of 6.29%.The firm had revenue of $383.54 million for the quarter, compared to analyst estimates of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. On average, equities research analysts forecast that Phibro Animal Health will post 3.03 earnings per share for the current year.

Phibro Animal Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 24th. Investors of record on Wednesday, June 3rd will be issued a dividend of $0.12 per share. The ex-dividend date is Wednesday, June 3rd. This represents a $0.48 dividend on an annualized basis and a yield of 0.8%. Phibro Animal Health's dividend payout ratio (DPR) is presently 21.33%.

More Phibro Animal Health News

Here are the key news stories impacting Phibro Animal Health this week:

• Positive Sentiment: Quarterly results beat: Phibro reported $0.76 EPS vs. $0.72 expected and revenue of $383.5M vs. $367.0M expected, with net income and sales up year-over-year — a near-term catalyst supporting the stock. Business Wire: Q3 Results
• Positive Sentiment: Dividend declared: Board approved a quarterly cash dividend of $0.12 per share (record June 3, payable June 24), which supports income-focused holders and signals management confidence in cash flow. Press Release / Dividend
• Positive Sentiment: Expanded credit facility: Management expanded the revolving credit facility to bolster liquidity — a near-term positive for financial flexibility and capital allocation. Yahoo: Revolving Credit Facility
• Neutral Sentiment: FY2026 guidance largely in line with Street: Management set EPS guidance of $2.98–$3.10 (consensus ~3.03) and revenue guidance about $1.5B — the midpoint is roughly consistent with analyst expectations, so guidance neither materially raised nor cut. Yahoo: Guidance
• Neutral Sentiment: Sustainability platform launch: Company introduced a companywide sustainable solutions platform and a VERRATAIN™ offering via partnership — positive for long-term ESG positioning but unlikely to be an immediate earnings driver. 01net: Sustainability Platform

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 7,040 shares of the company's stock in a transaction that occurred on Thursday, April 30th. The stock was sold at an average price of $52.76, for a total value of $371,430.40. Following the sale, the chief executive officer owned 74,760 shares in the company, valued at $3,944,337.60. This represents a 8.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 170,758 shares of company stock valued at $8,972,317 in the last 90 days. 50.13% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Phibro Animal Health

Hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC increased its holdings in shares of Phibro Animal Health by 4,227.1% in the fourth quarter. Millennium Management LLC now owns 641,313 shares of the company's stock valued at $23,959,000 after purchasing an additional 626,492 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Phibro Animal Health by 1,730.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 238,115 shares of the company's stock valued at $9,634,000 after buying an additional 225,110 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in Phibro Animal Health in the 3rd quarter valued at about $8,931,000. Advisors Preferred LLC acquired a new stake in Phibro Animal Health during the third quarter worth approximately $3,953,000. Finally, Lazard Asset Management LLC boosted its holdings in shares of Phibro Animal Health by 3,392.3% during the second quarter. Lazard Asset Management LLC now owns 92,441 shares of the company's stock worth $2,360,000 after acquiring an additional 89,794 shares during the period. Institutional investors and hedge funds own 99.34% of the company's stock.

About Phibro Animal Health

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.